On June 27, the medical network of xinhua medical treatment of a steady increase or will be settled.
On June 24th, shandong xinhua medical instrument co., LTD., said the company was in shandong province sasac approval, agreed to adjust the non-public shares, issue price of not less than the future issued 90% of an average of 20 trading days before the first trading, plans to raise funds not more than 1.947 billion yuan.
In fact, the new xinhua medical plan has lasted more than a year and a half. In early November 13, 2015, xinhua medical proposed price increases to 26.14 yuan/share, plans to raise a value of 2.936 billion yuan, but because of large secondary market volatility, sponsor business makes increase plans such as checked this sorry tale, finally raise large discount.
On June 26, the relevant person in charge of xinhua medical securities do in an interview with the 21st century economic report reporter, said the xinhua medical gained "settled", recognised by the national government, the next step is to implement as planned.
MaiSiKang lai Shi Lichen founder, points out that the increase for xinhua medical development is crucial, can effectively supplement the cash flow, reduce the asset-liability ratio, more important is if increases the success of the whole medical research and development layout, will move forward according to planning, enhance the market competition strength.
19.47 billion plus code main industry
It is understood that the non-public fund-raising total does not exceed 1.947 billion yuan, 98.03 million yuan for high temperature sterilization supplies project, 98.97 million yuan for emerging medical equipment product research and development and the pilot project, 134.03 million yuan for the advanced manufacturing technology upgrading, 1.03356 billion yuan to specialized subject hospital construction and upgrading project. The rest is used for replenishing current funds.
, according to xinhua medical main business including medical equipment, pharmaceutical equipment and medical service three major parts, the main products include infection control products, sterilization products, pharmaceutical equipment, radiation therapy, X-ray diagnostic products, medical products environmental protection equipment, etc.
Xinhua medical, points out that the increase is in order to adapt to the trend of the development of the medical equipment industry, seize the rapid growth of a good market opportunity for medical devices industry, realize the product structure upgrade, accelerate the development of business, improve the market competition ability of enterprise, to improve the company's core competitiveness and laying a foundation for sustained profitability.
In fact, if this is a success, it would be a "timely rain in dry land" for xinhua medical treatment. The relevant person in charge of xinhua sickness certificate generation to 21st century business herald reporter pointed out that though the constant increase of performance does not produce what effect, but some raised funds can reduce the financial expenses, if the public offering is advancing step by step, for the secondary market can also play a boost.
In the non-public issue of A share stock plan (the second revision), xinhua medical notes that in the last two years, the asset liability ratio of xinhua medical treatment is more than 50 %. At the end of 2014, late 2015 and the end of 2016, the asset-liability ratio of xinhua medical treatment was 57.21%, 59.61% and 64.65% respectively, significantly higher than the weighted average of 25.50%, 25.92% and 24.40% of the same industry.
"The company's debt level is higher, need to improve the capital structure. Through the non-public raise money, the rate of assets and liabilities of the company will be reduced to 55.20%, help the company improve capital strength, improve the financial situation, reduce the risk of insolvency, lay a foundation for the healthy and stable development of the company." Xinhua medical points out.
Mr. Shi pointed out that the success of the new China medical development is undoubtedly a great positive for xinhua medical development. At present medical industry mergers and acquisitions, are in transition, if there is sufficient capital, the xinhua medical can increasing update product research and development for its big health the whole industry chain platform provides sufficient operating funds support.
"At present, countries to support domestic medical equipment, domestic demand for medical services, a comprehensive upgrade there are a lot of development opportunities, if not kept pace in the transformation and upgrading, will pull open gap left behind by your competitors." "He said.
Xinhua medical in non-public a-share stock plan (revised) for the second time also points out that the health of China's 2020 strategy research report clearly pointed out that the self-developed drugs, medical supplies, medical equipment and large medical equipment, the ministry of health launched 10 billion yuan of the national health industry major projects. These special projects will provide a powerful impetus for the development of domestic medical devices.
That's a lot of ups and downs
In fact, xinhua medical it must increase, from planning matters related to increase in October 2015, to June 23, 2017 again won the approval of the state-owned assets supervision and administration commission of shandong province encountered in advance "accidental" for many times, lead to raise also dwindling.
As early as October 8, 2015, is planned by the xinhua medical announcement for non-public stock items, the company stock since October 8, 2015, were suspended and twice because there's significant uncertainty in view of the matter and release to continue the suspension notice, until the resumption of November 4, 2015.
Then throw out the first plan, proposed by 26.14 yuan/share price to shandong energy and health care, shandong xinhua medical instrument for the first phase of the employee stock ownership plan, cicc beautiful day (tianjin) equity investment partnership (limited partnership), and other eight investors will increase to raise no more than 2.936 billion yuan.
But as the secondary market, xinhua medical price and price increases appear upside down, in 2016 at the end of April to modify the set plan, will increase from 26.14 yuan/share price down to not less than 23.79 yuan/share, the total figure is down to 2.166 billion yuan.
On November 26, 2016, the new xinhua medical treatment after replacing the sponsor was revised to set the price for 23.72 yuan/unit, raising a total of 19.47 billion yuan. Finally, on December 21, 2016, xinhua medical service received notification from the SFC, and the sponsor changed to the international securities.
On June 10, 2017, xinhua medical institute issued A share plan of A share stock (the second revision) of the non-public offering of A shares, which still raised A total of 19.47 billion yuan. On June 23, 2017, the state-owned assets supervision and administration commission of shandong province approved the new xinhua medical treatment plan as the basic "setting up".
While bullish on the increase, Mr Shi also points out that there are uncertainties about the implementation of projects that raise money for investment. "Huge research and development of medical cost money, the success rate is relatively low, even if all raise money invested or may not have too much gain; and the health care industry has particularity, especially affected by the policy, also has a lot of uncertainty."
Such a pre-ipo project now gives xinhua medical headaches.
2014, xinhua medical by issuing stocks and pay cash for Germany in chengdu biological pharmaceutical equipment technology co., LTD. (hereinafter referred to as Britain) in chengdu 85% shares, the transaction price of 370 million yuan, and nine people, such as SuiChong signed "and pay cash purchase of assets through issuing shares profit forecast compensation agreement, promise after 4 years to complete the agreement between the two sides results, but in the second year of chengdu Britain failed to reach agreement, the performance is the loss of 51.5589 million yuan in 2016.
On June 22, the company announced that the court had accepted the lawsuit against the compensation of 9 people, such as sui chung, in 2016. |
